Psilocybin Alpha

Psychedelic Sector Insights

The definitive resource for analysis of the emergent psychedelic medicine sector. Cut through the noise with exclusive news, interviews, data and opportunities to invest in psychedelics.

40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health crisis.

After decades of repression, psychedelic research is thriving.

Promising research has already resulted in FDA Breakthrough Therapy designations for psilocybin-assisted therapies aimed at treating depression, and MDMA-assisted psychotherapy for PTSD. Research on other psychedelics, including MDMA and LSD, is picking up pace with research centres at prestigious institutions—including Johns Hopkins and Imperial College London—driving a new wave of psychedelic research.

Decriminalisation and legalisation campaigns are succeeding.

Last year the U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with California and New Jersey poised to follow suit. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.

Significant clinical trial milestones on the horizon.

An MDMA-assisted psychotherapy for PTSD trial is set to complete this year. The trial’s sponsor, MAPS, has raised $30 million to seek FDA approval for the treatment upon completion of the groundbreaking study. Two trials of psilocybin for depression are in Phase 2, having demonstrated safety in earlier stages.

Psychedelics have the potential to address depression anxiety addiction PTSD

Welcome to the Psychedelic Renaissance.

Year in Review: The Psychedelic Renaissance in 2020

We look back at some of the pivotal moments for psychedelics in 2020, a year of tremendous growth for psychedelic research, advocacy, and capital markets. We end by looking ahead to how the psychedelics space may continue to develop in 2021, which is poised to be another exciting and productive year.

Read our Year in Review

Popular Resources

Our most popular psychedelic sector resources.

Psychedelics Drug Development Tracker

A visual overview of drug development activity across the psychedelics space, including clinical trial stages.

Visit the Resource

New Resource

Psychedelic Sector Overview

Explore the Psychedelic Sector Landscape visually using our new tool.

Visit the Resource

Companies we follow...

Get the Latest News and Analaysis

Join our Newsletter

Psychedelic insights and interviews delivered to your inbox, including our weekly Bulletin.

Real-time Insights on Twitter

Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.

The Psychedelic Renaissance in Context

Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.

The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.

1943

Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.

mid 1960s – 1971

Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.

~10,000 BCE

Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.

1950s and ’60s

Fertile decades for psychedelics research and experimentation, particularly in the U.S.

21st Century

Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.